Gilead Sciences, Inc. (GILD)

Get GILD Alerts
*Delayed - data as of Sep. 3, 2015  -  Find a broker to begin trading GILD now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    GILD After Hours
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
Basic Chart Interactive Chart
Company Headlines Press Releases Market Stream
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Gilead Sciences Inc. (GILD)

Q3 2010 Earnings Call

October 19, 2010 05:30 pm ET


Susan Hubbard - VP of IR

John Milligan - President and COO

John Martin - Chairman and CEO

Kevin Young - EVP, Commercial Operations

Norbert Bischofberger - EVP, Research and Development and CSO

Robin Washington - SVP and CFO


Geoff Meacham - JPMorgan

Mark Schoenebaum - ISI

Rachel McMinn - Banc of America Merrill Lynch

Yaron Werber - Citigroup

Josh Schimmer - Leerink Swann

Ian Somaiya - Piper Jaffrey

Geoffrey Porges - Sanford Bernstein

Thomas Wei - Jefferies & Company

Jason Kantor - RBC Capital Markets

Tom Russo - Robert W. Baird

Phil Nadeau - Cowen & Co.

Joel Sendek - Lazard Capital Markets

Robyn Karnauskas - Deutsche Bank

Jim Birchenough - Barclays Capital

Jason Zhang - BMO Capital Markets

Maged Shenouda - Stifel Nicolaus

Geoff Meacham - JPMorgan



Ladies and gentlemen, thank you for standing by and welcome to the Gilead Sciences third quarter 2010 earnings conference call. My name is Stacey and I will be your conference operator for today.

At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. As a reminder, this conference call is being recorded today, October 19, 2010.

I would now like to turn the call over to Susan Hubbard, Vice President of Investor Relations. Please go ahead.

Susan Hubbard

Thank you, Stacey and good afternoon everyone. Welcome to Gilead's third quarter 2010 earnings conference call. We issued a press release this afternoon providing earnings results for the quarter. This press release is available on our website at as are the slides that provide much more detail around the topics discussed today on this call. Similar to the format we introduced on our last earnings call, our prepared comments will be brief to allow more time for your questions.

Our speakers today will be John Milligan, President and Chief Operating Officer and John Martin, Chairman and Chief Executive Officer who will provide some comments on this quarter and our view about future and opportunities for the company. Norbert Bischofberger, Executive Vice President of R&D and Chief Scientific Officer, Robin Washington, Senior Vice President and Chief Financial Officer and Kevin Young, Executive Vice President of Commercial Operations are here as well for the Q&A session.

I would first like to remind you that we will be making statements relating to future events, expectations, trends, objectives and financial results that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

These statements are based on certain assumptions and are subject to a number of risks and uncertainties that could cause our actual results to differ materially from those expressed in any forward-looking statements. I refer you to our latest SEC disclosure documents and recent press releases for a detailed description of risk factors and other matters related to our business. In addition please note that we undertake no obligation to update or revise these forward-looking statements. We will be making certain references to financial measures that are on a non-GAAP basis. We provide a reconciliation between GAAP and non-GAAP number in the press release we just issued and on our corporate website at

I will now turn the call over to John Milligan.

John Milligan

Thanks Susan. Gilead posted strong third quarter 2010 results with non-GAAP net income of almost $760 million or $0.90 per share representing a year-over-year increase in net income and EPS of 4% and 15% respectively.

Sales growth was strong with total revenues of just over $1.94 billion, up 8% year-over-year. Antiviral product sales were record $1.65 billion, up 12% year-over-year.

The US contributed $923 million for antiviral product sales increasing 15% year-over-year, resulting from the continued strong growth in patients and market share in the US and up 4% sequentially despite the added impact of rebates to ADAP and PHS as mandated by healthcare reforms.

There are now over 600,000 HIV inspected patients in the US taking antiretroviral therapy and we believe we are started to see the impact of DHHS guidelines endorsing earlier treatment.

Europe contributed $614 million to our antiviral product sales increasing 5% year-over-year and 2% sequentially. Although we saw demand growth for our products across Europe including clinical trial purchases totaling $10 million, this is partially offset by the fourth quarter impact of mandated price reductions and fluctuations in foreign exchange rates as we described on our second quarter call.

The products in our cardiovascular franchise namely Letairis and Ranexa delivered strong year-over-year growth of 26% and 23% respectively but were relatively flat sequentially. Both products saw demand growth that was paired back by small adjustments in wholesale inventories as well as changes in average selling price due to selective discounts in to managed care.

Our newest product Cayston achieved nearly $15 million in its second full quarter sales in both the US and some countries of Europe. In June we presented data from our head-to-head study of Cayston versus TOBI showing statistical superiority over TOBI at day 28 and we were presenting a six month data from the study at the North American Cystic Fibrosis Conference taking place in Baltimore later this week. We continue to receive positive responses from the CF community as the importance of having an additional treatment option and a null antibiotic to address the growing incidence of TOBI resistance and intolerance.

We continue to be vigilant on expense management resulting in a very healthy non-GAAP operating margin nearly 55% and we generated $740 million in operating cash flow for the quarter. And we have also been aggressive in our $5 billion share repurchase program having a repurchase retired $1.55 billion worth of stock or more than 45 million shares during the third quarter alone.

Read the rest of this transcript for free on